Keywords: Sanofi-Aventis, Regeneron, Research collaboration, Licensing, Monoclonal antibodies

Sanofi-Aventis expands deal with Regeneron to $160 million pa to end 2017

Article | 11 November 2009

France’s Sanofi-Aventis and USA-based Regeneron Pharmaceutical have entered into an agreement to expand and extend their existing global collaboration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in